Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Giada Bianchi
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
Recruiting - Brigham and Women'S Hospital
Boston, Massachusetts, United States
Recruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - Tufts Medical Center
Boston, Massachusetts, United States
Recruiting - Cleaveland Clinic
Cleveland, Ohio, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Nov 2024
- Primary completion
- 1 Jan 2029
- Completion
- 1 Jul 2029
- Last update posted
- 19 Aug 2026
- Registered enrollment
- 49
- Registry id
- NCT06569147
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.